Industry NewsClinical Diagnostics Thermo Fisher Scientific’s Oncomine Dx Target Test receives FDA approval
Industry NewsLife Sciences Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
